Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps

Ayrmid has proposed to acquire Bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of$6.84 per share payable upon achieving a net sales milestone. In February 2025, Bluebird entered into a definitive agreement with Carlyle and SK Capital Partners to be acquired and taken private for $3.00 per share in cash and a one-time contingent value right of$6.84 per share payable upon achievement of a net sales milestone. Bluebird Bio, Inc. BLUE received an unsolicited, non- ...